AVCO
Avalon GloboCare Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Avalon GloboCare Corp. is a clinical-stage, vertically integrated, leading CellTech bio-developer dedicated to advancing and empowering innovative, transformative immune effector cell therapy, exosome technology, as well as COVID-19 related diagnostics and therapeutics. Avalon also provides strategic advisory and outsourcing services to facilitate and enhance its clients' growth and development, as well as competitiveness in healthcare and CellTech industry markets. Through its subsidiary structure with unique integration of verticals from innovative R&D to automated bioproduction and accelerated clinical development, Avalon is establishing a leading role in the fields of cellular immunotherapy (including CAR-T/NK), exosome technology (ACTEX™), and regenerative therapeutics.
Market Cap: 62.5 Million
Primary Exchange: NASDAQ
Website: www.avalon-globocare.com
Shares Outstanding: 99.2 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 0.8042321936512145
Sector: Health Care and Social Assistance
Industry: General Medical and Surgical Hospitals
Ethical Flags
Longest drawdown: 1788 trading days
From: 2019-01-22 To: 2022-11-09
Lowest Point:
Avalon GloboCare President and CEO David Jin, M.D., Ph.D. to Chair the "Research and Application of Stem Cell Exosomes" Session at This Year's Second International Aesthetic Industry Conference
via: PR Newswire at 2019-06-13 04:00:00:000
FREEHOLD, N.J. , June 13, 2019 /PRNewswire/ --Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, announced today the Company's President and Chief Executive Officer, David Jin . M.D., Ph.D., will participate at the Second … read more...
Avalon GloboCare Announces Completion of Clinical-Grade Exosome Bio-Production Standardization with Launch of "ACTEX" Product Commercialization
via: PR Newswire at 2019-06-10 04:00:00:000
FREEHOLD, N.J. , June 10, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has achieved a major milestone in bio-production standardization of clinical-grade stem cell derived exos… read more...
Avalon GloboCare Announces Completion of Clinical-Grade Exosome Bio-Production Standardization with Launch of "ACTEX" Product Commercialization
via: PR Newswire at 2019-06-10 04:00:00:000
FREEHOLD, N.J. , June 10, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has achieved a major milestone in bio-production standardization of clinical-grade stem cell derived exos… read more...
Avalon GloboCare Announces Completion of Clinical-Grade Exosome Bio-Production Standardization with Launch of "ACTEX" Product Commercialization
via: PR Newswire at 2019-06-10 04:00:00:000
FREEHOLD, N.J. , June 10, 2019 /PRNewswire/ -- Avalon GloboCare Corp. (NASDAQ: AVCO), a leading global developer of cell-based technologies and therapeutics, today announced it has achieved a major milestone in bio-production standardization of clinical-grade stem cell derived exos… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|